Cargando…
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls f...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146450/ https://www.ncbi.nlm.nih.gov/pubmed/35632595 http://dx.doi.org/10.3390/v14050854 |
_version_ | 1784716566468755456 |
---|---|
author | Hu, Longbo Xu, Yuhua Wu, Liping Feng, Jin Zhang, Lu Tang, Yongjie Zhao, Xiang Mai, Runming Chen, Liyun Mei, Lingling Tan, Yuanzhen Du, Yingying Zhen, Yanping Su, Wenhan Peng, Tao |
author_facet | Hu, Longbo Xu, Yuhua Wu, Liping Feng, Jin Zhang, Lu Tang, Yongjie Zhao, Xiang Mai, Runming Chen, Liyun Mei, Lingling Tan, Yuanzhen Du, Yingying Zhen, Yanping Su, Wenhan Peng, Tao |
author_sort | Hu, Longbo |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls for the design of new potent vaccines targeting the emerging variant. However, since most vaccines approved and in clinical trials are based on the sequence of the original SARS-CoV-2 strain, the immunogenicity and protective efficacy of vaccines based on the B.1.351 variant remain largely unknown. In this study, we evaluated the immunogenicity, induced neutralization activity, and protective efficacy of wild-type spike protein nanoparticle (S-2P) and mutant spike protein nanoparticle (S-4M-2P) carrying characteristic mutations of B.1.351 variant in mice. Although there was no significant difference in the induction of spike-specific IgG responses in S-2P- and S-4M-2P-immunized mice, neutralizing antibodies elicited by S-4M-2P exhibited noteworthy, narrower breadth of reactivity with SARS-CoV-2 variants compared with neutralizing antibodies elicited by S-2P. Furthermore, the decrease of induced neutralizing antibody breadth at least partly resulted from the amino acid substitution at position 484. Moreover, S-4M-2P vaccination conferred insufficient protection against live SARS-CoV-2 virus infection, while S-2P vaccination gave definite protection against SARS-CoV-2 challenge in mice. Together, our study provides direct evidence that the E484K substitution in a SARS-CoV-2 subunit protein vaccine limited the cross-reactive neutralizing antibody breadth in mice and, more importantly, draws attention to the unfavorable impact of this mutation in spike protein of SARS-CoV-2 variants on the induction of potent neutralizing antibody responses. |
format | Online Article Text |
id | pubmed-9146450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91464502022-05-29 The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice Hu, Longbo Xu, Yuhua Wu, Liping Feng, Jin Zhang, Lu Tang, Yongjie Zhao, Xiang Mai, Runming Chen, Liyun Mei, Lingling Tan, Yuanzhen Du, Yingying Zhen, Yanping Su, Wenhan Peng, Tao Viruses Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls for the design of new potent vaccines targeting the emerging variant. However, since most vaccines approved and in clinical trials are based on the sequence of the original SARS-CoV-2 strain, the immunogenicity and protective efficacy of vaccines based on the B.1.351 variant remain largely unknown. In this study, we evaluated the immunogenicity, induced neutralization activity, and protective efficacy of wild-type spike protein nanoparticle (S-2P) and mutant spike protein nanoparticle (S-4M-2P) carrying characteristic mutations of B.1.351 variant in mice. Although there was no significant difference in the induction of spike-specific IgG responses in S-2P- and S-4M-2P-immunized mice, neutralizing antibodies elicited by S-4M-2P exhibited noteworthy, narrower breadth of reactivity with SARS-CoV-2 variants compared with neutralizing antibodies elicited by S-2P. Furthermore, the decrease of induced neutralizing antibody breadth at least partly resulted from the amino acid substitution at position 484. Moreover, S-4M-2P vaccination conferred insufficient protection against live SARS-CoV-2 virus infection, while S-2P vaccination gave definite protection against SARS-CoV-2 challenge in mice. Together, our study provides direct evidence that the E484K substitution in a SARS-CoV-2 subunit protein vaccine limited the cross-reactive neutralizing antibody breadth in mice and, more importantly, draws attention to the unfavorable impact of this mutation in spike protein of SARS-CoV-2 variants on the induction of potent neutralizing antibody responses. MDPI 2022-04-21 /pmc/articles/PMC9146450/ /pubmed/35632595 http://dx.doi.org/10.3390/v14050854 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hu, Longbo Xu, Yuhua Wu, Liping Feng, Jin Zhang, Lu Tang, Yongjie Zhao, Xiang Mai, Runming Chen, Liyun Mei, Lingling Tan, Yuanzhen Du, Yingying Zhen, Yanping Su, Wenhan Peng, Tao The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title | The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title_full | The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title_fullStr | The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title_full_unstemmed | The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title_short | The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice |
title_sort | e484k substitution in a sars-cov-2 spike protein subunit vaccine resulted in limited cross-reactive neutralizing antibody responses in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146450/ https://www.ncbi.nlm.nih.gov/pubmed/35632595 http://dx.doi.org/10.3390/v14050854 |
work_keys_str_mv | AT hulongbo thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT xuyuhua thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT wuliping thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT fengjin thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhanglu thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT tangyongjie thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhaoxiang thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT mairunming thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT chenliyun thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT meilingling thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT tanyuanzhen thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT duyingying thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhenyanping thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT suwenhan thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT pengtao thee484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT hulongbo e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT xuyuhua e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT wuliping e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT fengjin e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhanglu e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT tangyongjie e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhaoxiang e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT mairunming e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT chenliyun e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT meilingling e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT tanyuanzhen e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT duyingying e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT zhenyanping e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT suwenhan e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice AT pengtao e484ksubstitutioninasarscov2spikeproteinsubunitvaccineresultedinlimitedcrossreactiveneutralizingantibodyresponsesinmice |